Get the Stockscreener App
2.51
8.06%
-0.22
Annovis Bio Inc stock is traded at $2.51, with a volume of 349.63K.
It is down -8.06% in the last 24 hours and up +7.73% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$2.73
Open:
$2.7
24h Volume:
349.63K
Relative Volume:
0.80
Market Cap:
$48.91M
Revenue:
-
Net Income/Loss:
$-40.94M
P/E Ratio:
-0.6536
EPS:
-3.84
Net Cash Flow:
$-22.97M
1W Performance:
-13.15%
1M Performance:
+7.73%
6M Performance:
-48.46%
1Y Performance:
-72.39%
1-Day Range:
$2.36
$2.7186
1-Week Range:
$2.36
$2.9698
52-Week Range:
$1.11
$10.54
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.51 | 53.20M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
What are Annovis Bio Inc. company’s key revenue driversChart Pattern Ideas For Fast Growth - jammulinksnews.com
What catalysts could drive Annovis Bio Inc. stock higher in 2025Swing Trade Insights With Proven Results - jammulinksnews.com
Annovis Bio Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrade Insight With Community Collaboration Supported - metal.it
Will Annovis Bio Inc. stock split in the near futureChart-Based Trade Entries Gain Analyst Support - metal.it
How does Annovis Bio Inc. compare to its industry peersBuild wealth faster with consistent growth stocks - jammulinksnews.com
Is Annovis Bio Inc. stock overvalued or undervaluedCapitalize on strong market momentum - jammulinksnews.com
What is Annovis Bio Inc. company’s growth strategyMaximize your returns with expert insights - jammulinksnews.com
Should I hold or sell Annovis Bio Inc. stock in 2025Accelerated capital growth - jammulinksnews.com
Is Annovis Bio Inc. a growth stock or a value stockConsistently exceptional gains - jammulinksnews.com
How many analysts rate Annovis Bio Inc. as a “Buy”Maximize your portfolio’s growth potential - jammulinksnews.com
What makes Annovis Bio Inc. stock price move sharplyHigh-yield growth strategies - jammulinksnews.com
Why Annovis Bio Inc. stock attracts strong analyst attentionBreakout Momentum Stocks - metal.it
Annovis Bio Inc. Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Is Annovis Bio Inc. a good long term investmentFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Annovis Bio Inc. stockExceptional growth trajectory - PrintWeekIndia
Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors - TipRanks
What drives Annovis Bio Inc. stock priceMassive portfolio appreciation - jammulinksnews.com
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio to Present Key Findings at Alzheimer’s Association International Conference - MSN
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):